[A13-44] Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 17.03.2014
Project no.:
A13-44
Commission:
Commission awarded on 03.12.2013 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-12 | Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-44 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-12 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-15 | Second Addendum to Commission A13-44 (ipilimumab, new therapeutic indication) | Commission completed |
| A14-11 | Addendum to Commission A13-44 (ipilimumab, new therapeutic indication) | Commission completed |
| A12-07 | Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A20-116 | Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2014-06-05 A G-BA decision was published.